Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Hepatocellular 18Colorectal Neoplasms 17Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 9Advanced Solid Tumor 9Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Esophageal Neoplasms 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Midazolam 2Injections 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pembrolizumab 1pamiparib 1lenvatinib 1drospirenone 1cemiplimab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × tislelizumab × 1 year × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡